Bioengineered artificial skin is a medical device that is developed through the cultivation of living human cells on biologically active scaffolds to replace damaged or defective skin. It is used in the treatment of severe burns and chronic wounds. These artificial skin grafts aid in wound healing by acting as semi-permeable barriers and protecting tissues from infection and fluid loss. They support re-epithelialization and allow for vascularization from the wound bed.

The global bioengineered artificial skin market is estimated to be valued at US$ 3.32 Bn in 2023 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
Rising incidences of burn and trauma injuries leading to severe burns due to increasing occurrence of fire accidents and violence are the major factors driving the growth of the global bioengineered artificial skin market. According to the World Health Organization (WHO), burns are responsible for around 300,000 deaths worldwide each year. Moreover, changing lifestyles have increased the prevalence of several skin diseases such as psoriasis, atopic dermatitis, and diabetic foot ulcers further fueling the demand for bioengineered artificial skin. For instance, itching and flaking of skin due to psoriasis significantly impacts the quality of life of patients. Artificial skins have thus emerged as an effective treatment option to heal wounds for such infections. With increasing research and developmental activities in regenerative medicine field, new innovative bioengineered skin substitutes providing better healing outcomes are expected to enter the market during the forecast period.

SWOT Analysis

Strength: Bioengineered artificial skin offers an alternative to skin grafts for severe burn victims. It can be manufactured on a large scale to treat a large number of patients. It facilitates wound healing and reduces chances of infection and scarring.

Weakness: The technology is still in development phase and long term effectiveness is still being researched. High cost of treatment can limit its widespread adoption. Dependence on donor cells can cause availability issues.

Opportunity: Rising number of burn injuries and trauma cases worldwide presents a huge patient pool. Growing awareness about benefits of advanced wound care treatments will drive the market. Partnerships between manufacturers and healthcare providers can boost access.

Threats: Presence of alternative therapies such as skin grafts limits sole reliance on this technology. Strong bargaining power of healthcare providers can affect pricing. Stringent regulatory approvals and clinical trials delay market entry of new players.


Key Takeaways

The global bioengineered artificial skin market is expected to witness high growth over the forecast period of 2023 to 2030 on account of rising incidence of burn injuries and increasing adoption of advanced wound care therapies. The market size is projected to reach $US 3.32 Billion by 2023, growing at an estimated CAGR of 16%.

Regional analysis - North America dominates the global market currently due to high awareness levels and wide acceptance of advanced treatment options. However, Asia Pacific is anticipated to grow at the fastest pace owing to large patient population, growing healthcare expenditure, and increasing expertise in tissue engineering field in countries like China and India.

Key players - Key players operating in the bioengineered artificial skin market are Genoskin, Smith and Nephew Inc., Genzyme Biosurgery, Vericel Corporation, AROA BIOSURGERY LIMITED, Integra LifeSciences Corp, COOK BIOTECH, Mölnlycke Health Care AB, Avita Medical, MiMedx Group, Inc., and Organogenesis Holdings Inc. These companies are focusing on new product launches and collaborations to strengthen their market position.